TY - JOUR
T1 - Medulloblastomas with ELP1 pathogenic variants
T2 - A weakly penetrant syndrome with a restricted spectrum in a limited age window
AU - Guerrini-Rousseau, Léa
AU - Masliah-Planchon, Julien
AU - Filser, Mathilde
AU - Tauziède-Espariat, Arnault
AU - Entz-Werle, Natacha
AU - Maugard, Christine M.
AU - Hopman, Saskia M.J.
AU - Torrejon, Jacob
AU - Gauthier-Villars, Marion
AU - Simaga, Fatoumata
AU - Blauwblomme, Thomas
AU - Beccaria, Kevin
AU - Rouleau, Etienne
AU - Dimaria, Marina
AU - Grill, Jacques
AU - Abbou, Samuel
AU - Claret, Béatrice
AU - Brugières, Laurence
AU - Doz, François
AU - Bouchoucha, Yassine
AU - Faure-Conter, Cécile
AU - Bonadona, Valerie
AU - Mansuy, Ludovic
AU - De Carli, Emilie
AU - Ingster, Olivier
AU - Legrand, Clémentine
AU - Pagnier, Anne
AU - Berthet, Pascaline
AU - Bodet, Damien
AU - Julia, Sophie
AU - Bertozzi, Anne Isabelle
AU - Wilems, Marjolaine
AU - Maurage, Claude Alain
AU - Delattre, Olivier
AU - Ayrault, Olivier
AU - Dufour, Christelle
AU - Bourdeaut, Franck
N1 - Publisher Copyright:
© 2024 The Author(s).
PY - 2024/1/1
Y1 - 2024/1/1
N2 - Background: ELP1 pathogenic variants (PV) have been recently identified as the most frequent variants predisposing to Sonic Hedgehog (SHH) medulloblastomas (MB); however, guidelines are still lacking for genetic counseling in this new syndrome. Methods: We retrospectively reviewed clinical and genetic data of a French series of 29 ELP1-mutated MB. Results: All patients developed SHH-MB, with a biallelic inactivation of PTCH1 found in 24 tumors. Other recurrent alterations encompassed the TP53 pathway and activation of MYCN/MYCL signaling. The median age at diagnosis was 7.3 years (range: 3-14). ELP1-mutated MB behave as sporadic cases, with similar distribution within clinical and molecular risk groups and similar outcomes (5 y - OS=86%); no unusual side effect of treatments was noticed. Remarkably, a germline ELP1 PV was identified in all patients with available constitutional DNA (n=26); moreover, all tested familial trio (n=11) revealed that the PVs were inherited. Two of the 26 index cases from the French series had a family history of MB; pedigrees from these patients and from 1 additional Dutch family suggested a weak penetrance. Apart from MB, no cancer was associated with ELP1 PVs; second tumors reported in 4 patients occurred within the irradiation fields, in the usual time-lapse for expected radiotherapy-induced neoplasms. Conclusions: The low penetrance, the "at risk' age window limited to childhood and the narrow tumor spectrum, question the actual benefit of genetic screening in these patients and their family. Our results suggest restricting ELP1 germline sequencing to patients with SHH-MB, depending on the parents"request.
AB - Background: ELP1 pathogenic variants (PV) have been recently identified as the most frequent variants predisposing to Sonic Hedgehog (SHH) medulloblastomas (MB); however, guidelines are still lacking for genetic counseling in this new syndrome. Methods: We retrospectively reviewed clinical and genetic data of a French series of 29 ELP1-mutated MB. Results: All patients developed SHH-MB, with a biallelic inactivation of PTCH1 found in 24 tumors. Other recurrent alterations encompassed the TP53 pathway and activation of MYCN/MYCL signaling. The median age at diagnosis was 7.3 years (range: 3-14). ELP1-mutated MB behave as sporadic cases, with similar distribution within clinical and molecular risk groups and similar outcomes (5 y - OS=86%); no unusual side effect of treatments was noticed. Remarkably, a germline ELP1 PV was identified in all patients with available constitutional DNA (n=26); moreover, all tested familial trio (n=11) revealed that the PVs were inherited. Two of the 26 index cases from the French series had a family history of MB; pedigrees from these patients and from 1 additional Dutch family suggested a weak penetrance. Apart from MB, no cancer was associated with ELP1 PVs; second tumors reported in 4 patients occurred within the irradiation fields, in the usual time-lapse for expected radiotherapy-induced neoplasms. Conclusions: The low penetrance, the "at risk' age window limited to childhood and the narrow tumor spectrum, question the actual benefit of genetic screening in these patients and their family. Our results suggest restricting ELP1 germline sequencing to patients with SHH-MB, depending on the parents"request.
KW - ELP1
KW - cancer predisposition syndrome
KW - medulloblastoma
KW - pathogenic variant
UR - http://www.scopus.com/inward/record.url?scp=85198094979&partnerID=8YFLogxK
U2 - 10.1093/noajnl/vdae075
DO - 10.1093/noajnl/vdae075
M3 - Article
AN - SCOPUS:85198094979
SN - 2632-2498
VL - 6
JO - Neuro-Oncology Advances
JF - Neuro-Oncology Advances
IS - 1
M1 - vdae075
ER -